Dr. Kalish's research focuses on understanding the molecular and epigenetic mechanisms that contribute to the predisposition to cancer that is characteristic of pediatric patients with rare imprinted gene disorders, including the overgrowth disorder Beckwith-Wiedemann syndrome (BWS).
The Kalish Lab studies the genetic and epigenetic causes of growth disorders and cancer predisposition. The lab focuses on studying Beckwith-Wiedemann syndrome (BWS), the most common epigenetic and cancer predisposition disorder, and also runs the BWS registry and biorepository.
As part of its commitment to training the next generation of pediatric pioneers, every year CHOP Research takes time to honor its exceptional trainees, and recently announced the 2014 Distinguished Research Trainee Award winners.
From cancer drugs designed to match a child's specific molecular abnormality, to a phone app that can offer a dermatologic diagnosis quicker than an office visit, the future of children's healthcare is unfolding right before our eyes at the Children's Hospital of Philadelphia Research Institute.
Super Bowl Sunday is right around the corner, and our biweekly installment of In the News is the perfect playing field for us to showcase the wide range of research projects that Children's Hospital of Philadelphia experts tackle. Huddle up!
It was weekend of firsts on many fronts, as physicians, genetic counselors, nurses, researchers, and families gathered July 21–23 at Children’s Hospital of Philadelphia Research Institute for the inaugural Deciphering Beckwith-Wiedemann syndrome (BWS) conference. BWS is a rare overgrowth disorder involving genetic and epigenetic changes that occur approximately every one in 10,500 births.